Tenapanor
Brand and Other Names:
IBSRELA, XPHOZAH
Mechanism of Action:
Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.
Indications:
IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Route:
Oral
Dose:
The recommended dosage in adults is 50 mg, orally twice daily.
Adverse Reactions:
Most common adverse reactions (≥2%) are diarrhea, abdominal distension, flatulence and dizziness.
Contraindication:
- Pediatric patients less than 6 years of age.
- Patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions:
Diarrhea: Patients may experience severe diarrhea. If severe diarrhea occurs, suspend dosing and rehydrate patient.
See package insert for full prescribing information.